Alx Oncology Holdings (ALXO) Net Income towards Common Stockholders Growth (3y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 47.10% |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 15.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.74% |
| Dec 31, 2025 | 9.34% |
| Sep 30, 2025 | 14.41% |
| Jun 30, 2025 | 7.62% |
| Mar 31, 2025 | -7.82% |
| Dec 31, 2024 | -0.84% |
| Sep 30, 2024 | -7.72% |
| Jun 30, 2024 | -34.27% |
| Mar 31, 2024 | -35.85% |
| Dec 31, 2023 | 89.92% |
| Sep 30, 2023 | -67.97% |
| Jun 30, 2023 | -35.14% |
| Mar 31, 2023 | -59.68% |
| Dec 31, 2022 | -51.37% |
| Sep 30, 2022 | -104.73% |
| Jun 30, 2022 | -85.24% |